Viking Therapeutics Inc VKTX
News
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial — Update
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22


